Safety and Efficacy Study of the Treatment of Humerus Fractures

June 17, 2026 updated by: IlluminOss Medical, Inc.

CE Marking Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Humerus Fractures

The purpose of this study is to collect safety and performance data on the use of the Photodynamic Bone Stabilization System (PBSS) when used to provide stabilization and alignment for the treatment of acute humerus fractures.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cologne, Germany, D-50733
        • St. Vinzenz-Hospital GmbH
      • Gummersbach, Germany, 51643
        • Klinikum Oberberg GmbH
      • Wetzlar, Germany, 35578
        • Lahn-Dill Kliniken
      • Breda, Netherlands, 4818 CK
        • Amphia Hospital
      • Dordrecht, Netherlands, 3318 AT
        • Albert Schweitzer Hospital
      • Maastricht, Netherlands, 6229 HX
        • University Hospital Maastricht

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

46 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Fracture-Specific Inclusion Criteria

  1. Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 (The Netherlands); AO Classification 11A1, 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 and 13A1, 13A2 and 13B1, 13B2 (Germany).
  2. Fracture is closed, Gustilo Type I or II.

    General Inclusion Criteria

  3. Skeletally mature men and women, 50 years of age or older (The Netherlands only) or 61 years of age or older (Germany only) at time of index injury.
  4. a) Female patients of child bearing potential agree to use double barrier method of contraception (The Netherlands only) b) Female patients of non-child bearing potential must meet one of the following criteria (The Netherlands only):

    • Postmenopausal for at least 1 year, or
    • Documented oophorectomy or hysterectomy, or
    • Surgically sterile
  5. Willing and able to understand and sign the informed consent.

Fracture-Specific Exclusion Criteria

  1. Index treatment is greater than 28 days (The Netherlands only) or 14 days (Germany only) post fracture
  2. Open fractures with severe contamination.
  3. Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable.
  4. Marked bone loss or bone resorption patients, who due to a prior delayed union or non-union of the bones or other illnesses, may not be able to have their fracture adequately reduced prior to placement of the IlluminOss-device. This could leave bone void spaces that would preclude the device from maintaining alignment of the fractured bone.
  5. Previous fracture of affected limb.

    General Exclusion Criteria

  6. Pregnant or lactating (The Netherlands only).
  7. Patients with a contralateral fracture of the forearm or humerus (Germany only).
  8. Active or incompletely treated infections that could involve the site where the device will be implanted.
  9. Distant foci of infections that may spread to the implant site
  10. Uncooperative patients or patients, who are incapable of following directions (for example as a consequence of a neurological or psychiatric disorder).
  11. Concomitant metabolic disorders that may impair bone formation.
  12. Osteomalacia.
  13. Allergic to implant materials or dental glue.
  14. Vascular insufficiency, muscular atrophy, or neuro-muscular disease.
  15. Polytrauma patients (multiple injuries resulting from a high-impact event, eg- a motor vehicle accident).
  16. Life expectancy less than one year due to concurrent illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Photodynamic Bone Stabilization System (PBSS)
The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
Treatment of acute humerus fractures

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Normal Radiographic Fracture Healing
Time Frame: 180 days
Two of four cortices or two of four views demonstrating bridging on standard radiographs
180 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of Complete Radiographic Healing
Time Frame: 180 and 360 days
Three of four cortices or three of four views demonstrating bridging, with dissolution of the majority (greater than or equal to 75% on orthogonal views) of fracture lines
180 and 360 days
Evaluation of Normal Radiographic Healing
Time Frame: 360 days
Two of four cortices or two of four views demonstrating bridging on standard radiographs
360 days
Summary of Pain VAS
Time Frame: 180 and 360 days
Change from baseline of pain visual analog score (VAS). Participants indicate their pain level by marking a point along a continuous horizontal line anchored by "No Pain" and "Severe Pain. Total score range: 0 to 100 units on a scale 0 = No pain 100 = Severe pain. Lower scores represent a better outcome (less pain), while higher scores represent a worse outcome (greater pain)
180 and 360 days
Summary of DASH Score
Time Frame: 180 and 360 days
Change from baseline of disability of the arm shoulder and hand (DASH) score. DASH Disability/Symptom Total Score range: 0 to 100 units on a scale 0 = No disability/symptoms; 100 = Most severe disability/symptoms. Each item is scored on a 5-point Likert scale. Lower scores represent a better outcome (less disability and fewer symptoms), while higher scores represent a worse outcome (greater disability and more severe symptoms)
180 and 360 days
Summary of Constant Shoulder Score
Time Frame: 180 and 360 days
Change from baseline of constant shoulder score. Total Constant Score range: 0 to 100 units on a scale 0 = Worst shoulder function; 100 = Best shoulder function. The total Constant Score is calculated by summing the four subscale scores for a maximum of 100 points. Higher scores represent a better outcome (improved shoulder function and less pain), while lower scores represent a worse outcome (greater disability and impaired shoulder function).
180 and 360 days
Summary of Pain on Palpation
Time Frame: 180 and 360 days
Pain at Palpation (yes/no), grade and clinical significance. Grade: mild, moderate, severe
180 and 360 days
Summary of Return to Pre-Fracture Mobility
Time Frame: 180 and 360 days
Summary of subjects who returned to pre-fracture mobility (yes/no)
180 and 360 days
Summary of Range of Motion
Time Frame: 180 and 360 days
Summary of range of motion (active and passive) for affected and unaffected arm, for abduction, flexion, extension and lateral and medial rotation.
180 and 360 days
Summary of Disability Status
Time Frame: 180 and 360 days
Disability status as determined by the investigator
180 and 360 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Actual)

May 1, 2017

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

March 16, 2015

First Submitted That Met QC Criteria

March 16, 2015

First Posted (Estimated)

March 20, 2015

Study Record Updates

Last Update Posted (Actual)

July 15, 2026

Last Update Submitted That Met QC Criteria

June 17, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 12-03-EUHUM-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Humerus Fractures

Clinical Trials on Photodynamic Bone Stabilization System

Subscribe